Heparin 100U/L for Prevention of PVC Complications
- Conditions
- Peripheral Venous Catheter ComplicationsOcclusionEcchymosisPhlebitis
- Registration Number
- NCT01131754
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Brief Summary
Flushes with saline solution are used for maintaining patency of peripheral intermittent intravenous catheters in many institution based on the results of previous studies showing that 10 U heparin/mL is not better than saline in this respect. The latest meta-analysis investigated also safety and efficacy of heparin concentrations of 100 U/ml used as an intermittent flush, but no firm conclusion was reached because of limitations of the few available studies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 214
- requiring i.v. therapy for an expected duration longer than five days
- admitted to the 3rd medical ward of IRCCS Policlinico San Matteo
- bleeding tendency
- platelet count less than 100 x 109/L
- coagulation defects
- previous adverse reaction to heparin
- programmed cytotoxic therapy
- inability to give an informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Phlebitis or Occlusion Phlebitis is defined as the presence of two or more symptoms/signs among pain, tenderness, warmth, erythema, swelling, or a palpable cord (score of ≥ 2 according to the Visual Infusion Phlebitis Score). Occlusion is defined as resistance to flushing as evidenced by the inability to administer 1 ml of flushing solution within 30 seconds.
- Secondary Outcome Measures
Name Time Method Ecchymosis Ecchymosis is defined as a purple discoloration of the skin around the catheter insertion site larger than 1 cm.
Heparin induced thrombocytopenia Heparin induced thrombocytopenia is defined as a fall in platelet count \> 50% of baseline value without any alternative explanation. To detect this phenomenon, platelet count is to be performed at baseline and, subsequently, every 5 days.
Trial Locations
- Locations (1)
Medicina 3 - IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
Medicina 3 - IRCCS Policlinico San Matteo🇮🇹Pavia, Italy